128 related articles for article (PubMed ID: 38364110)
21. Voxelotor for the treatment of sickle cell disease.
Vissa M; Vichinsky E
Expert Rev Hematol; 2021 Mar; 14(3):253-262. PubMed ID: 33602029
[No Abstract] [Full Text] [Related]
22. Reduced oxygen extraction efficiency in sickle cell anemia patients with evidence of cerebral capillary shunting.
Juttukonda MR; Donahue MJ; Waddle SL; Davis LT; Lee CA; Patel NJ; Pruthi S; Kassim AA; Jordan LC
J Cereb Blood Flow Metab; 2021 Mar; 41(3):546-560. PubMed ID: 32281458
[TBL] [Abstract][Full Text] [Related]
23. Hemodynamic mechanisms underlying elevated oxygen extraction fraction (OEF) in moyamoya and sickle cell anemia patients.
Watchmaker JM; Juttukonda MR; Davis LT; Scott AO; Faraco CC; Gindville MC; Jordan LC; Cogswell PM; Jefferson AL; Kirshner HS; Donahue MJ
J Cereb Blood Flow Metab; 2018 Sep; 38(9):1618-1630. PubMed ID: 28029271
[TBL] [Abstract][Full Text] [Related]
24. Voxelotor (GBT440) produces interference in measurements of hemoglobin S.
Rutherford NJ; Thoren KL; Shajani-Yi Z; Colby JM
Clin Chim Acta; 2018 Jul; 482():57-59. PubMed ID: 29601794
[No Abstract] [Full Text] [Related]
25. Real-world data on voxelotor to treat patients with sickle cell disease.
Muschick K; Fuqua T; Stoker-Postier C; Anderson AR
Eur J Haematol; 2022 Aug; 109(2):154-161. PubMed ID: 35460521
[TBL] [Abstract][Full Text] [Related]
26. Voxelotor treatment of a patient with sickle cell disease and very severe anemia.
Shet AS; Mendelsohn L; Harper J; Ostrowski D; Henry ER; Gwaabe E; Nichols J; Alayash AI; Eaton WA; Thein SL
Am J Hematol; 2019 Apr; 94(4):E88-E90. PubMed ID: 30592074
[No Abstract] [Full Text] [Related]
27. Effect of voxelotor on cardiopulmonary testing in youths with sickle cell anemia in a pilot study.
Phan V; Hershenson J; Caldarera L; Larkin SK; Wheeler K; Cortez AL; Dulman R; Briere N; Lewis A; Kuypers FA; Yang E
Pediatr Blood Cancer; 2023 Aug; 70(8):e30423. PubMed ID: 37247190
[TBL] [Abstract][Full Text] [Related]
28. The impact of voxelotor treatment on leg ulcers in patients with sickle cell disease.
Minniti CP; Knight-Madden J; Tonda M; Gray S; Lehrer-Graiwer J; Biemond BJ
Am J Hematol; 2021 Apr; 96(4):E126-E128. PubMed ID: 33476432
[No Abstract] [Full Text] [Related]
29. An expert review of voxelotor for the treatment of hemolytic anemia in patients with sickle cell disease: 'bridging the gap between laboratory data and patient related outcomes'.
Inusa BPD; Mnika K; Babiker S
Expert Rev Hematol; 2023; 16(8):585-591. PubMed ID: 37329253
[TBL] [Abstract][Full Text] [Related]
30. Voxelotor: First Approval.
Blair HA
Drugs; 2020 Feb; 80(2):209-215. PubMed ID: 32020554
[TBL] [Abstract][Full Text] [Related]
31. Hemodynamic provocation with acetazolamide shows impaired cerebrovascular reserve in adults with sickle cell disease.
Václavů L; Meynart BN; Mutsaerts HJMM; Petersen ET; Majoie CBLM; VanBavel ET; Wood JC; Nederveen AJ; Biemond BJ
Haematologica; 2019 Apr; 104(4):690-699. PubMed ID: 30523051
[TBL] [Abstract][Full Text] [Related]
32. The efficacy of voxelotor, 900 mg in patients with sickle cell anaemia: A meta-analysis of the randomised controlled trials.
Tanriverdi LH; Sarici A; Erkurt MA; Parlakpinar H
Int J Clin Pract; 2021 Jun; 75(6):e13967. PubMed ID: 33369007
[TBL] [Abstract][Full Text] [Related]
33. How do we monitor hemoglobin S in patients who undergo red blood cell exchange and take voxelotor?
Godbey EA; Anderson MR; M Bachmann L; Sanford KW; Wieditz K; Roseff SD
Transfusion; 2021 Jun; 61(6):1680-1683. PubMed ID: 33880770
[No Abstract] [Full Text] [Related]
34. Non-invasive imaging of oxygen extraction fraction in adults with sickle cell anaemia.
Jordan LC; Gindville MC; Scott AO; Juttukonda MR; Strother MK; Kassim AA; Chen SC; Lu H; Pruthi S; Shyr Y; Donahue MJ
Brain; 2016 Mar; 139(Pt 3):738-50. PubMed ID: 26823369
[TBL] [Abstract][Full Text] [Related]
35. Red cell exchange transfusions increase cerebral capillary transit times and may alter oxygen extraction in sickle cell disease.
DeBeer T; Jordan LC; Waddle S; Lee C; Patel NJ; Garza M; Davis T; Pruthi S; Jones S; Donahue MJ
NMR Biomed; 2023 May; 36(5):e4889. PubMed ID: 36468659
[TBL] [Abstract][Full Text] [Related]
36. Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis.
Shah N; Lipato T; Alvarez O; Delea T; Lonshteyn A; Weycker D; Nguyen A; Beaubrun A; Agodoa I
Expert Rev Hematol; 2022 Feb; 15(2):167-173. PubMed ID: 35191358
[TBL] [Abstract][Full Text] [Related]
37. Cerebral perfusion characteristics show differences in younger versus older children with sickle cell anaemia: Results from a multiple-inflow-time arterial spin labelling study.
Kawadler JM; Hales PW; Barker S; Cox TCS; Kirkham FJ; Clark CA
NMR Biomed; 2018 Jun; 31(6):e3915. PubMed ID: 29601112
[TBL] [Abstract][Full Text] [Related]
38. Quantification of whole-brain oxygenation extraction fraction and cerebral metabolic rate of oxygen consumption in adults with sickle cell anemia using individual T
Li W; Xu X; Liu P; Strouse JJ; Casella JF; Lu H; van Zijl PCM; Qin Q
Magn Reson Med; 2020 Mar; 83(3):1066-1080. PubMed ID: 31483528
[TBL] [Abstract][Full Text] [Related]
39. Sickle hemoglobin oxygen affinity-shifting strategies have unequal cerebrovascular risks.
Hebbel RP; Hedlund BE
Am J Hematol; 2018 Mar; 93(3):321-325. PubMed ID: 29150874
[No Abstract] [Full Text] [Related]
40. Urgent use of voxelotor in sickle cell disease when immediate transfusion is not safe.
Ferlis M; Lipato T; Roseff SD; Smith WR
Eur J Haematol; 2022 Nov; 109(5):586-589. PubMed ID: 35848827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
